We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+39.57%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.03B
AUM Growth
+$88.2M
Cap. Flow
-$124M
Cap. Flow %
-12.03%
Top 10 Hldgs %
68.92%
Holding
48
New
–
Increased
4
Reduced
21
Closed
8

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$9.02M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$7.49M
3
IMNM icon
Immunome
IMNM
+$1.5M
4
NGNE icon
Neurogene
NGNE
+$449K

Top Sells

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$35.1M
2
REPL icon
Replimune Group
REPL
+$26.4M
3
HNGE
Hinge Health
HNGE
+$15.5M
4
BHVN icon
Biohaven
BHVN
+$10.3M
5
BSX icon
Boston Scientific
BSX
+$9.16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRA icon
26
Atara Biotherapeutics
ATRA
$92.3M
$6.33M 0.62%
441,701
– –
FOLD
27
DELISTED
Amicus Therapeutics
FOLD
$6.12M 0.6%
777,178
-411,820
-35% -$2.93M
ALXO icon
28
ALX Oncology
ALXO
$277M
$6.1M 0.59%
3,332,983
-58,472
-2% -$50.6K
ESTA icon
29
Establishment Labs
ESTA
$2.11B
$5.3M 0.52%
129,364
-7,131
-5% -$291K
CBLL
30
CeriBell Inc
CBLL
$911M
$5M 0.49%
435,239
– –
XERS icon
31
Xeris Biopharma Holdings
XERS
$1.55B
$3.67M 0.36%
451,099
– –
VTYX
32
DELISTED
Ventyx Biosciences
VTYX
$3.34M 0.32%
1,073,386
-41,143
-4% -$109K
LVTX
33
DELISTED
LAVA Therapeutics
LVTX
$3.24M 0.31%
2,074,372
– –
RPTX
34
DELISTED
Repare Therapeutics
RPTX
$2.79M 0.27%
1,586,174
– –
IVVD icon
35
Invivyd
IVVD
$284M
$2.51M 0.24%
2,285,320
– –
PLRX icon
36
Pliant Therapeutics
PLRX
$68.7M
$2.36M 0.23%
1,591,695
-40,882
-3% -$62.4K
REPL icon
37
Replimune Group
REPL
$1.46B
$2.25M 0.22%
535,818
-4,128,973
-89% -$26.4M
PRME icon
38
Prime Medicine
PRME
$655M
$483K 0.05%
87,118
-1,987,232
-96% -$8.07M
KLRS
39
Kalaris Therapeutics
KLRS
$95.9M
$479K 0.05%
82,955
– –
BOLD
40
Boundless Bio
BOLD
$64.4M
$302K 0.03%
245,458
-343,576
-58% -$397K
BHVN icon
41
Biohaven
BHVN
$2.33B
– –
-729,515
Closed -$10.3M
BSX icon
42
Boston Scientific
BSX
$67.9B
– –
-85,301
Closed -$9.16M
FDMT icon
43
4D Molecular Therapeutics
FDMT
$810M
– –
-112,168
Closed -$416K
IGMS
44
DELISTED
IGM Biosciences
IGMS
– –
-2,952,131
Closed -$3.31M
KYMR icon
45
Kymera Therapeutics
KYMR
$9.82B
– –
-803,289
Closed -$35.1M
PEN icon
46
Penumbra
PEN
$12.7B
– –
-18,818
Closed -$4.83M
VERV
47
DELISTED
Verve Therapeutics
VERV
– –
-740,261
Closed -$8.31M
HNGE
48
Hinge Health
HNGE
$7.05B
– –
-300,000
Closed -$15.5M
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2025 Portfolio in Review

As of Q3 2025, Redmile Group held 48 positions worth $1.03B, up 9.4% from $940M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Redmile Group withdrew a net $124M in Q3 2025, closing 8 positions and reducing 21 holdings. Its most notable exit was Kymera Therapeutics, an estimated $35.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Redmile Group added an estimated $9.02M to Cogent Biosciences.

  • Redmile Group added most to Cogent Biosciences in Q3 2025, an estimated $9.02M increase.
  • Redmile Group's biggest Q3 2025 reduction was Replimune Group, cutting an estimated $26.4M.
  • Redmile Group fully exited Kymera Therapeutics in Q3 2025, selling an estimated $35.1M.
  • Redmile Group's ten largest holdings make up 69% of its $1.03B portfolio in Q3 2025.
  • Redmile Group opened 0 new positions and closed 8 in Q3 2025.
  • Redmile Group's portfolio value rose 9.4% quarter-over-quarter to $1.03B.

Based on Redmile Group's 13F filing for Q3 2025, filed 14 Nov 2025.